Search

everythinglearnresearchcommunity

for

Search:↓

Upadacitinib is safe and effective for treating alopecia areata and atopic dermatitis in children.

Ruxolitinib significantly improves multiple autoimmune conditions in APS-1 patients.

Pioglitazone, Trimipramine, and Dimetindene may be repurposed to treat psoriasis.

Deuruxolitinib effectively treats alopecia areata but may cause manageable side effects.

The drug Olumiant is now approved to treat severe hair loss from alopecia and can also be used for some hospitalized COVID-19 patients.

Upadacitinib effectively treats severe alopecia areata and is safe.

Deucravacitinib improves symptoms and reduces inflammation in Lichen Planopilaris.

Deuruxolitinib is FDA-approved for treating severe alopecia areata.

Omalizumab can cause temporary hair loss but still works well for chronic urticaria.

Dupilumab can help regrow hair and improve skin conditions in patients with severe atopic dermatitis and alopecia areata.

A parasite molecule can speed up skin healing and reduce scarring.

Deucravacitinib helped a man regrow hair and improve psoriasis.

TGPC plus CGT is effective and safe for treating severe alopecia areata in children.

Baricitinib effectively improved both atopic dermatitis and alopecia areata symptoms in a patient.

Aggressive immunosuppressive treatment improved a woman's severe heart condition linked to autoimmune disease.

Janus kinase inhibitors may effectively treat resistant scalp conditions like folliculitis decalvans and dissecting cellulitis.

Chronic autoimmune urticaria can be managed with specific therapies and requires improved diagnosis and treatment methods.

Rezpegaldesleukin shows promise for treating severe alopecia areata.

Abrocitinib may effectively treat Lichen Planopilaris.

Deuruxolitinib improves hair regrowth in alopecia areata but needs more safety research.

Long-term Imiquimod treatment causes initial skin inflammation that lessens over time, and topical corticosteroids reduce this inflammation and cytokines in a mouse model of psoriasis.

Tofacitinib nanoparticles can safely and effectively treat alopecia areata by targeting hair follicles.

Emulgels effectively deliver hydrophobic drugs for skin conditions like acne and psoriasis.

The gel effectively reduced folliculitis symptoms and was safe to use.

Patients with Systemic Sclerosis have much higher levels of GDF-15, which could help predict organ involvement and guide treatment.

Tofacitinib helped a young woman's severe hair loss and arthritis but not her plaque psoriasis.

Topical tofacitinib is a safe and effective treatment for autoimmune skin disorders.